Review



a549 lung cancer cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC a549 lung cancer cells
    Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of <t>A549</t> cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).
    A549 Lung Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 35502 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 lung cancer cells/product/ATCC
    Average 99 stars, based on 35502 article reviews
    a549 lung cancer cells - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer"

    Article Title: Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer

    Journal: International Journal of Molecular Medicine

    doi: 10.3892/ijmm.2026.5735

    Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).
    Figure Legend Snippet: Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).

    Techniques Used: Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Expressing, Cell Culture, Two Tailed Test

    Impact of CAFs on anti-PD-L1 immunotherapy resistance in lung cancer cells via LCN2 expression. (A) Simplified flowchart depicting how CAFs influence anti-PD-L1 immunotherapy resistance in lung cancer cells through LCN2 expression. (B) Cell Counting Kit-8 assay assessing the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. C-sh-NC. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay investigating the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL staining analyzing the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI in blue fluorescence. (F) Measurement of intracellular Fe 2+ and ROS levels (scale bar, 25 µm); *P<0.05, **P<0.01 and ***P<0.001; all cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B-F). CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sh-, short hairpin; NC, negative control; Fe 2+ , iron; ns, not significant (P>0.05).
    Figure Legend Snippet: Impact of CAFs on anti-PD-L1 immunotherapy resistance in lung cancer cells via LCN2 expression. (A) Simplified flowchart depicting how CAFs influence anti-PD-L1 immunotherapy resistance in lung cancer cells through LCN2 expression. (B) Cell Counting Kit-8 assay assessing the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. C-sh-NC. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay investigating the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL staining analyzing the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI in blue fluorescence. (F) Measurement of intracellular Fe 2+ and ROS levels (scale bar, 25 µm); *P<0.05, **P<0.01 and ***P<0.001; all cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B-F). CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sh-, short hairpin; NC, negative control; Fe 2+ , iron; ns, not significant (P>0.05).

    Techniques Used: Expressing, Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Negative Control



    Similar Products

    99
    ATCC a549 lung cancer cells
    Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of <t>A549</t> cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).
    A549 Lung Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 lung cancer cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    a549 lung cancer cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human lung cancer cell lines a549
    IFNs mediate immunotherapy-associated gene expression in tumors and activate immune cells in healthy PBMCs. A qPCR was used to detect the PD-L1 expression in <t>A549</t> (5 × 10 5 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). B The expression of the top 8 up-regulated genes from RNAseq analysis (Table S2), including ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were validated by qPCR analysis in A549 treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). C The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNs (20 ng/mL for each, incubated for 24 h), co-cultured with A549, IFNα- and IFNγ (3 h)-pretreated A549 at a 20:1 ratio, and IFNα, IFNγ, and A549 concurrently treated for 24 h were analyzed by flow cytometry to (D and E) detect the activation marker CD107a levels in CD4 + T, CD8 + T cells, and CD45 + CD3 − (nonT) PBMCs (n = 3). CD4 + T and CD8 + T were gated by staining with anti-CD45-Pacific blue, anti-CD3-APC/Cy7, anti-CD8-Alexa488, and anti-CD4-PE. CD107a was detected using anti-CD107a-BV605. (F) In addition, the activation markers IFNG, and cytotoxic marker granzyme B (GZMB) were detected by qPCR in the collected PBMCs after individual treatments. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001
    Human Lung Cancer Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lung cancer cell lines a549/product/ATCC
    Average 99 stars, based on 1 article reviews
    human lung cancer cell lines a549 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC non small cell lung cancer
    IFNs mediate immunotherapy-associated gene expression in tumors and activate immune cells in healthy PBMCs. A qPCR was used to detect the PD-L1 expression in <t>A549</t> (5 × 10 5 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). B The expression of the top 8 up-regulated genes from RNAseq analysis (Table S2), including ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were validated by qPCR analysis in A549 treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). C The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNs (20 ng/mL for each, incubated for 24 h), co-cultured with A549, IFNα- and IFNγ (3 h)-pretreated A549 at a 20:1 ratio, and IFNα, IFNγ, and A549 concurrently treated for 24 h were analyzed by flow cytometry to (D and E) detect the activation marker CD107a levels in CD4 + T, CD8 + T cells, and CD45 + CD3 − (nonT) PBMCs (n = 3). CD4 + T and CD8 + T were gated by staining with anti-CD45-Pacific blue, anti-CD3-APC/Cy7, anti-CD8-Alexa488, and anti-CD4-PE. CD107a was detected using anti-CD107a-BV605. (F) In addition, the activation markers IFNG, and cytotoxic marker granzyme B (GZMB) were detected by qPCR in the collected PBMCs after individual treatments. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001
    Non Small Cell Lung Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non small cell lung cancer/product/ATCC
    Average 99 stars, based on 1 article reviews
    non small cell lung cancer - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human lung cancer cell line a549
    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid <t>A549</t> cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
    Human Lung Cancer Cell Line A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lung cancer cell line a549/product/ATCC
    Average 99 stars, based on 1 article reviews
    human lung cancer cell line a549 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human non small cell lung cancer cell line a549
    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid <t>A549</t> cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
    Human Non Small Cell Lung Cancer Cell Line A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human non small cell lung cancer cell line a549/product/ATCC
    Average 99 stars, based on 1 article reviews
    human non small cell lung cancer cell line a549 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC remarkable anti proliferative activity against non small cell lung cancer cell lines
    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid <t>A549</t> cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
    Remarkable Anti Proliferative Activity Against Non Small Cell Lung Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/remarkable anti proliferative activity against non small cell lung cancer cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    remarkable anti proliferative activity against non small cell lung cancer cell lines - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC a549 lung cancer cell line
    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid <t>A549</t> cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
    A549 Lung Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 lung cancer cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    a549 lung cancer cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC non small cell lung cancer cell lines a549
    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid <t>A549</t> cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
    Non Small Cell Lung Cancer Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non small cell lung cancer cell lines a549/product/ATCC
    Average 99 stars, based on 1 article reviews
    non small cell lung cancer cell lines a549 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).

    Journal: International Journal of Molecular Medicine

    Article Title: Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer

    doi: 10.3892/ijmm.2026.5735

    Figure Lengend Snippet: Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).

    Article Snippet: In the present study, A549 lung cancer cells [cat. no. CCL-185; American Type Culture Collection (ATCC)] were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), while 293T cells (cat. no. CRL-3216; ATCC) were maintained in DMEM/F12 medium with 10% FBS.

    Techniques: Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Expressing, Cell Culture, Two Tailed Test

    Impact of CAFs on anti-PD-L1 immunotherapy resistance in lung cancer cells via LCN2 expression. (A) Simplified flowchart depicting how CAFs influence anti-PD-L1 immunotherapy resistance in lung cancer cells through LCN2 expression. (B) Cell Counting Kit-8 assay assessing the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. C-sh-NC. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay investigating the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL staining analyzing the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI in blue fluorescence. (F) Measurement of intracellular Fe 2+ and ROS levels (scale bar, 25 µm); *P<0.05, **P<0.01 and ***P<0.001; all cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B-F). CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sh-, short hairpin; NC, negative control; Fe 2+ , iron; ns, not significant (P>0.05).

    Journal: International Journal of Molecular Medicine

    Article Title: Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer

    doi: 10.3892/ijmm.2026.5735

    Figure Lengend Snippet: Impact of CAFs on anti-PD-L1 immunotherapy resistance in lung cancer cells via LCN2 expression. (A) Simplified flowchart depicting how CAFs influence anti-PD-L1 immunotherapy resistance in lung cancer cells through LCN2 expression. (B) Cell Counting Kit-8 assay assessing the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. C-sh-NC. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay investigating the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL staining analyzing the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI in blue fluorescence. (F) Measurement of intracellular Fe 2+ and ROS levels (scale bar, 25 µm); *P<0.05, **P<0.01 and ***P<0.001; all cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B-F). CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sh-, short hairpin; NC, negative control; Fe 2+ , iron; ns, not significant (P>0.05).

    Article Snippet: In the present study, A549 lung cancer cells [cat. no. CCL-185; American Type Culture Collection (ATCC)] were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), while 293T cells (cat. no. CRL-3216; ATCC) were maintained in DMEM/F12 medium with 10% FBS.

    Techniques: Expressing, Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Negative Control

    IFNs mediate immunotherapy-associated gene expression in tumors and activate immune cells in healthy PBMCs. A qPCR was used to detect the PD-L1 expression in A549 (5 × 10 5 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). B The expression of the top 8 up-regulated genes from RNAseq analysis (Table S2), including ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were validated by qPCR analysis in A549 treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). C The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNs (20 ng/mL for each, incubated for 24 h), co-cultured with A549, IFNα- and IFNγ (3 h)-pretreated A549 at a 20:1 ratio, and IFNα, IFNγ, and A549 concurrently treated for 24 h were analyzed by flow cytometry to (D and E) detect the activation marker CD107a levels in CD4 + T, CD8 + T cells, and CD45 + CD3 − (nonT) PBMCs (n = 3). CD4 + T and CD8 + T were gated by staining with anti-CD45-Pacific blue, anti-CD3-APC/Cy7, anti-CD8-Alexa488, and anti-CD4-PE. CD107a was detected using anti-CD107a-BV605. (F) In addition, the activation markers IFNG, and cytotoxic marker granzyme B (GZMB) were detected by qPCR in the collected PBMCs after individual treatments. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors

    doi: 10.1007/s00262-026-04300-7

    Figure Lengend Snippet: IFNs mediate immunotherapy-associated gene expression in tumors and activate immune cells in healthy PBMCs. A qPCR was used to detect the PD-L1 expression in A549 (5 × 10 5 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). B The expression of the top 8 up-regulated genes from RNAseq analysis (Table S2), including ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were validated by qPCR analysis in A549 treated with IFNα and IFNγ (20 ng/mL for each, incubated for 2 h). C The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNs (20 ng/mL for each, incubated for 24 h), co-cultured with A549, IFNα- and IFNγ (3 h)-pretreated A549 at a 20:1 ratio, and IFNα, IFNγ, and A549 concurrently treated for 24 h were analyzed by flow cytometry to (D and E) detect the activation marker CD107a levels in CD4 + T, CD8 + T cells, and CD45 + CD3 − (nonT) PBMCs (n = 3). CD4 + T and CD8 + T were gated by staining with anti-CD45-Pacific blue, anti-CD3-APC/Cy7, anti-CD8-Alexa488, and anti-CD4-PE. CD107a was detected using anti-CD107a-BV605. (F) In addition, the activation markers IFNG, and cytotoxic marker granzyme B (GZMB) were detected by qPCR in the collected PBMCs after individual treatments. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Article Snippet: The human lung cancer cell lines A549, HepG2, and PLC5 used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Gene Expression, Expressing, Incubation, RNA sequencing, Cell Culture, Flow Cytometry, Activation Assay, Marker, Staining, Two Tailed Test

    Radiotherapy increases IFNs and promotes immunogenic activity but distinct gene expression in the IFNγ- and 8 Gy-treated A549 cells. A A549 cells (5 × 10 5 in a 6-well plate) treated with irradiation (0, 1, 2, 4, 8 Gy) and further incubated for 24 h were collected to detect the p53-downstream gene CDKN1A, MDM2, and tumor marker MKI67 by qPCR. Statistical analysis was achieved by one-way ANOVA. B In addition, IFNA and IFNG and their downstream PD-L1 expression in the irradiated A549 cells and C MDM2 inhibitor Nutlin-3a-treated A549 cells were measured by qPCR. D The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each) for 2 h and 24 h were collected and analyzed for the immune activation marker IFNG and cytotoxic marker granzyme B (GZMB) expression using qPCR. E M1 markers TNFA and CXCL10, and M2 markers ARG1 and IL-10 were also investigated in the collected PBMCs with the individual treatments by qPCR. F The healthy PBMCs (1 × 10 6 in a 6-well plate) incubated with irradiation-treated A549 (0, 4, 8 Gy) at a ratio of 20:1 for 24 h were collected and investigated for the immune activation marker IFNG and cytotoxic marker GZMB expression using qPCR. G Meanwhile, M1 markers TNFA, CXCL10, and M2 markers ARG1, IL-10 were also investigated in the collected PBMCs with the individual treatments by qPCR. (H) RNAseq was used to search for the differential genes in the A549 cells (5 × 10 5 in a 6-well plate) treated with IFNγ (20 ng /mL, incubated for 2 h) and x-ray irradiation (8 Gy was selected based on the highest CDKN1A and MDM2 induction, 24 h post-irradiation). There were 75 up-regulated and 12 down-regulated genes selected in IFNγ-treated A549 and 88 up-regulated and 202 down-regulated genes selected in 8 Gy-treated A549 according to log2 fold change > 1 or < -1 with p value < 0.05 (Table S2-4). There was no overlapped gene between IFNγ and 8 Gy treatment. I The 75 and 88 up-regulated genes in IFNγ- and irradiated A549 cells were analyzed by NetworkAnalyst ( https://www.networkanalyst.ca/ ) based on the KEGG dataset, revealing that the differential genes were involved in STATs and p53 signaling pathways, respectively. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001. ns, non-significant

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors

    doi: 10.1007/s00262-026-04300-7

    Figure Lengend Snippet: Radiotherapy increases IFNs and promotes immunogenic activity but distinct gene expression in the IFNγ- and 8 Gy-treated A549 cells. A A549 cells (5 × 10 5 in a 6-well plate) treated with irradiation (0, 1, 2, 4, 8 Gy) and further incubated for 24 h were collected to detect the p53-downstream gene CDKN1A, MDM2, and tumor marker MKI67 by qPCR. Statistical analysis was achieved by one-way ANOVA. B In addition, IFNA and IFNG and their downstream PD-L1 expression in the irradiated A549 cells and C MDM2 inhibitor Nutlin-3a-treated A549 cells were measured by qPCR. D The healthy PBMCs (1 × 10 6 in a 6-well plate) treated with IFNα and IFNγ (20 ng/mL for each) for 2 h and 24 h were collected and analyzed for the immune activation marker IFNG and cytotoxic marker granzyme B (GZMB) expression using qPCR. E M1 markers TNFA and CXCL10, and M2 markers ARG1 and IL-10 were also investigated in the collected PBMCs with the individual treatments by qPCR. F The healthy PBMCs (1 × 10 6 in a 6-well plate) incubated with irradiation-treated A549 (0, 4, 8 Gy) at a ratio of 20:1 for 24 h were collected and investigated for the immune activation marker IFNG and cytotoxic marker GZMB expression using qPCR. G Meanwhile, M1 markers TNFA, CXCL10, and M2 markers ARG1, IL-10 were also investigated in the collected PBMCs with the individual treatments by qPCR. (H) RNAseq was used to search for the differential genes in the A549 cells (5 × 10 5 in a 6-well plate) treated with IFNγ (20 ng /mL, incubated for 2 h) and x-ray irradiation (8 Gy was selected based on the highest CDKN1A and MDM2 induction, 24 h post-irradiation). There were 75 up-regulated and 12 down-regulated genes selected in IFNγ-treated A549 and 88 up-regulated and 202 down-regulated genes selected in 8 Gy-treated A549 according to log2 fold change > 1 or < -1 with p value < 0.05 (Table S2-4). There was no overlapped gene between IFNγ and 8 Gy treatment. I The 75 and 88 up-regulated genes in IFNγ- and irradiated A549 cells were analyzed by NetworkAnalyst ( https://www.networkanalyst.ca/ ) based on the KEGG dataset, revealing that the differential genes were involved in STATs and p53 signaling pathways, respectively. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001. ns, non-significant

    Article Snippet: The human lung cancer cell lines A549, HepG2, and PLC5 used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Activity Assay, Gene Expression, Irradiation, Incubation, Marker, Expressing, Activation Assay, RNA sequencing, Protein-Protein interactions, Two Tailed Test

    Radiotherapy specifically suppresses TP53-wild type tumors. A Flow cytometry based on fluorescent Annexin V staining was used to detect apoptosis in the irradiation (0, 4, and 8 Gy)-treated TP53-wild type A549, HCT116, and TP53null HCT116 cells (5 × 10 5 in a 6-well plate) post 24 h culture. n = 2. B - C qPCR was used to validate the 13 irradiation-mediated genes from RNAseq (Table S3 and Table S4), including the increased MDM2, CYFIP2, STOM, and the decreased MKI67, CENPE, ARGHGAP11A, BRCA1, ASPM, ALAN, TOP2A, FANCI, TOPBP1, and ECT2, in (B) A549 treated with 8 Gy (24 h post-irradiation), C A549 treated with MDM2 inhibitor Nutlin-3a (10 µg/mL for 24 h). D and E qPCR was also used to detect p53-downstream CDKN1A and the selected 13 genes in TP53-wild type and TP53null HCT116 treated with 8 Gy of irradiation (24 h post-irradiation). n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors

    doi: 10.1007/s00262-026-04300-7

    Figure Lengend Snippet: Radiotherapy specifically suppresses TP53-wild type tumors. A Flow cytometry based on fluorescent Annexin V staining was used to detect apoptosis in the irradiation (0, 4, and 8 Gy)-treated TP53-wild type A549, HCT116, and TP53null HCT116 cells (5 × 10 5 in a 6-well plate) post 24 h culture. n = 2. B - C qPCR was used to validate the 13 irradiation-mediated genes from RNAseq (Table S3 and Table S4), including the increased MDM2, CYFIP2, STOM, and the decreased MKI67, CENPE, ARGHGAP11A, BRCA1, ASPM, ALAN, TOP2A, FANCI, TOPBP1, and ECT2, in (B) A549 treated with 8 Gy (24 h post-irradiation), C A549 treated with MDM2 inhibitor Nutlin-3a (10 µg/mL for 24 h). D and E qPCR was also used to detect p53-downstream CDKN1A and the selected 13 genes in TP53-wild type and TP53null HCT116 treated with 8 Gy of irradiation (24 h post-irradiation). n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Article Snippet: The human lung cancer cell lines A549, HepG2, and PLC5 used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Flow Cytometry, Staining, Irradiation, RNA sequencing, Two Tailed Test

    Radiotherapy induces IFNs in TP53-wild type tumors. A qPCR was used to detect the expression of IFNs in TP53-wild type HepG2, HCT116, TP53-mutant PLC5, and TP53null HCT116 (5 × 10 5 in a 6-well plate) treated with 0, 4, 8 Gy of irradiation (24 h post-irradiation). B The IFNγ-mediated up-regulated genes from RNAseq analysis (Table S2), including PD-L1, ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were investigated by qPCR in TP53-wild type and TP53null HCT116 (5 × 10 5 in a 6-well plate) treated with 8 Gy of irradiation (24 h post-irradiation). C The cultured medium from the irradiated A549 (0, 4, 8 Gy, post 24 h) was collected to treat parental A549 (5 × 10 5 in a 6-well plate) for 2 h. qPCR was used to measure the selected gene expression. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors

    doi: 10.1007/s00262-026-04300-7

    Figure Lengend Snippet: Radiotherapy induces IFNs in TP53-wild type tumors. A qPCR was used to detect the expression of IFNs in TP53-wild type HepG2, HCT116, TP53-mutant PLC5, and TP53null HCT116 (5 × 10 5 in a 6-well plate) treated with 0, 4, 8 Gy of irradiation (24 h post-irradiation). B The IFNγ-mediated up-regulated genes from RNAseq analysis (Table S2), including PD-L1, ICAM1, BATF, IRF1, SOCS1, HAPLN3, TAP1, PSMB9, and MAFF, were investigated by qPCR in TP53-wild type and TP53null HCT116 (5 × 10 5 in a 6-well plate) treated with 8 Gy of irradiation (24 h post-irradiation). C The cultured medium from the irradiated A549 (0, 4, 8 Gy, post 24 h) was collected to treat parental A549 (5 × 10 5 in a 6-well plate) for 2 h. qPCR was used to measure the selected gene expression. n = 3 and error bars were presented by SD in qPCR analysis. Statistical analysis was achieved by an unpaired two-tailed Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001

    Article Snippet: The human lung cancer cell lines A549, HepG2, and PLC5 used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

    Techniques: Expressing, Mutagenesis, Irradiation, RNA sequencing, Cell Culture, Gene Expression, Two Tailed Test

    Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid A549 cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Resistance of Lung CSCs to Oxidative Phosphorylation-Mediated ROS Production and Apoptosis Induction. (A) Cell viability in adherent and spheroid A549 cells treated with indicated concentrations of H 2 O 2 for 24 h (B Left) Annexin V-FITC/PI analysis of apoptosis in adherent and spheroid A549 cells following treatment with H 2 O 2 (100 μM or 250 μM) for 24 h (B Right) Quantification of viable cells. (C) Assessment of 8-oxo-dG levels and (D) comet assay analysis for measuring oxidative DNA damage in adherent and spheroid A549 cells treated without or with H 2 O 2 (250 μM) for 1, 3, 6, or 24 h (E Left) Representative time course of oxygen consumption rates (OCR) in adherent and spheroid A549 cells. (E Right) Quantification of different parameters is shown. (F) Fluorescence levels of Mitosox (mitochondrial superoxide indicator), HPF (hydroxyl radical indicator), or DCF (ROS indicator) in adherent and spheroid A549 cells, analyzed by flow cytometry. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Phospho-proteomics, Single Cell Gel Electrophoresis, Fluorescence, Flow Cytometry, Two Tailed Test

    Lung CSCs Resist ROS-Induced Cell Death through ACSL1 and ACSL4-Mediated Lipid Peroxidation. (A) Western blot showing ACSL1, ACSL4, and ACSL3 protein expression in adherent and spheroid cultures. (B) MDA level (left), 4-HNE level (middle), and ratio of C11-BODIPY 581/591 (right) were used to measure lipid peroxidation in spheroid A549 cells treated with H 2 O 2 (250 μM) and vehicle, TC (ACSL inhibitor, 10 μM) or RG (ACSL4 inhibitor, 20 μM) for 24 h (C, D, and E) Cell viability, 8-oxo-dG level, and comet assay in spheroid A549 cells treated with H 2 O 2 (250 μM) and vehicle, TC (10 μM) or RG (20 μM) for 24 h. Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Lung CSCs Resist ROS-Induced Cell Death through ACSL1 and ACSL4-Mediated Lipid Peroxidation. (A) Western blot showing ACSL1, ACSL4, and ACSL3 protein expression in adherent and spheroid cultures. (B) MDA level (left), 4-HNE level (middle), and ratio of C11-BODIPY 581/591 (right) were used to measure lipid peroxidation in spheroid A549 cells treated with H 2 O 2 (250 μM) and vehicle, TC (ACSL inhibitor, 10 μM) or RG (ACSL4 inhibitor, 20 μM) for 24 h (C, D, and E) Cell viability, 8-oxo-dG level, and comet assay in spheroid A549 cells treated with H 2 O 2 (250 μM) and vehicle, TC (10 μM) or RG (20 μM) for 24 h. Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Western Blot, Expressing, Single Cell Gel Electrophoresis

    Elevated TAG and Lipid Droplet Levels in Lung CSCs Compared to Ordinary Lung Cancer Cells. (A) Lipidomic analysis reveals the distribution of lipid classes in adherent and spheroid cultures of A549 and H1993 cells, analyzed by MS. (B) Pie charts illustrating the percentage of lipid classes within the total lipids in adherent and spheroid cultures of A549 and H1993 cells. (C) Venn diagram (left) and bar graph (right) showing overlap of lipid species with significant changes across adherent and spheroid cultures as detected by MS. (D) Heat map illustrating the clustering of 98 lipid species with significant changes across the adherent and spheroid cultures of A549 and H1993 cells. (E) Intracellular TAG concentrations analyzed using a TAG determination kit. (F) Ratios of lipid droplets measured using a lipid droplet isolation kit. (G) Cells were costained with BODIPY 493/503 (green) and perilipin 5 (red) in adherent and spheroid A549 cells, with cell nuclei counterstained with DAPI (blue). (H) Representative proximity ligation assay (PLA) images showing interaction between the mitochondria protein mitofusin 2 and the LDs-associated protein perilipin 1. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Elevated TAG and Lipid Droplet Levels in Lung CSCs Compared to Ordinary Lung Cancer Cells. (A) Lipidomic analysis reveals the distribution of lipid classes in adherent and spheroid cultures of A549 and H1993 cells, analyzed by MS. (B) Pie charts illustrating the percentage of lipid classes within the total lipids in adherent and spheroid cultures of A549 and H1993 cells. (C) Venn diagram (left) and bar graph (right) showing overlap of lipid species with significant changes across adherent and spheroid cultures as detected by MS. (D) Heat map illustrating the clustering of 98 lipid species with significant changes across the adherent and spheroid cultures of A549 and H1993 cells. (E) Intracellular TAG concentrations analyzed using a TAG determination kit. (F) Ratios of lipid droplets measured using a lipid droplet isolation kit. (G) Cells were costained with BODIPY 493/503 (green) and perilipin 5 (red) in adherent and spheroid A549 cells, with cell nuclei counterstained with DAPI (blue). (H) Representative proximity ligation assay (PLA) images showing interaction between the mitochondria protein mitofusin 2 and the LDs-associated protein perilipin 1. Data are presented as mean ± SD (student's two-tailed unpaired t -test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Isolation, Proximity Ligation Assay, Two Tailed Test

    Contribution of Oxidized TAG and Lipid Droplet to the Resistance of ROS-Induced Cell Death in Lung CSCs. (A) 1 H NMR spectra obtained from adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 24 h). The proton signal at 5.2–5.3 ppm corresponds to the glycerol backbone of TAG, while the proton signal at 5.6–5.7 ppm represents lipid peroxidation products. The fraction was quantified and normalized by the total protein amount. (B) Detection of the distribution of oxidized lipids (left) and the level of oxidized TAG (right) using LC-MS. (C) Measurement of TAG levels using LC-MS. (D) Levels of lipid droplets (fold change relative to Sph-CTR) after 24-h exposure to the following pro-oxidants: H 2 O 2 (250 μM), tBH (100 μM), ethanol (100 mM), FeCl 2 (0.25 mM) or hypoxia (1 % oxygen). (E) Representative immunofluorescence images showing costaining with C11-BODIPY 581/591 (oxidized, green) and LipidTOX (Lipid droplet, LD, red) in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h). Cell nuclei were counterstained with DAPI (blue). (F) Representative immunofluorescence images showing costaining with C11-BODIPY 581/591 (oxidized, green) and MitoBright (mitochondrion, Mito, red) in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h). Cell nuclei were counterstained with DAPI (blue). Arrows indicate colocalization, and pink arrows indicate non-colocalization. (G) Fluorescence levels of Mitosox in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h), analyzed by flow cytometry. (H) Time-dependent changes in the relative fluorescence intensity (RFI) of JC-1 in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM). Sph, Spheroid-A549; Adh, Adherent-A549; Sph-H, Spheroid-A549 + H 2 O 2 . Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test is employed in D; two-way ANOVA followed with Tukey's multiple comparison test is employed in G; student's two-tailed unpaired t -test is employed in H). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Contribution of Oxidized TAG and Lipid Droplet to the Resistance of ROS-Induced Cell Death in Lung CSCs. (A) 1 H NMR spectra obtained from adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 24 h). The proton signal at 5.2–5.3 ppm corresponds to the glycerol backbone of TAG, while the proton signal at 5.6–5.7 ppm represents lipid peroxidation products. The fraction was quantified and normalized by the total protein amount. (B) Detection of the distribution of oxidized lipids (left) and the level of oxidized TAG (right) using LC-MS. (C) Measurement of TAG levels using LC-MS. (D) Levels of lipid droplets (fold change relative to Sph-CTR) after 24-h exposure to the following pro-oxidants: H 2 O 2 (250 μM), tBH (100 μM), ethanol (100 mM), FeCl 2 (0.25 mM) or hypoxia (1 % oxygen). (E) Representative immunofluorescence images showing costaining with C11-BODIPY 581/591 (oxidized, green) and LipidTOX (Lipid droplet, LD, red) in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h). Cell nuclei were counterstained with DAPI (blue). (F) Representative immunofluorescence images showing costaining with C11-BODIPY 581/591 (oxidized, green) and MitoBright (mitochondrion, Mito, red) in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h). Cell nuclei were counterstained with DAPI (blue). Arrows indicate colocalization, and pink arrows indicate non-colocalization. (G) Fluorescence levels of Mitosox in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM, 6 h), analyzed by flow cytometry. (H) Time-dependent changes in the relative fluorescence intensity (RFI) of JC-1 in adherent and spheroid A549 cells treated with/without H 2 O 2 (250 μM). Sph, Spheroid-A549; Adh, Adherent-A549; Sph-H, Spheroid-A549 + H 2 O 2 . Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test is employed in D; two-way ANOVA followed with Tukey's multiple comparison test is employed in G; student's two-tailed unpaired t -test is employed in H). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Liquid Chromatography with Mass Spectroscopy, Immunofluorescence, Fluorescence, Flow Cytometry, Comparison, Two Tailed Test

    Increased TAG Synthesis in Lung CSCs via Upregulation of DGAT1/2 Expression. (A) Gene ontology (GO) analysis of RNA-sequencing data to identify spheroid-enriched genes between adherent and spheroid culture of A549 and H1993 cells. (B) Genes identified in TAG biosynthesis process term. (C) Western blot showing protein expression related to TAG biosynthesis process in adherent and spheroid culture. (D) Measurement of TAG levels in spheroid A549 cells treated with vehicle, DGAT1i (DGAT1 inhibitor, PF-04620110, 10 μM), DGAT2i (DGAT2 inhibitor, PF-06424439, 10 μM), or DGAT1i + DGAT2i for 24 h. (E) BODIPY 493/503 staining (green) for lipid droplets in spheroid A549 cells treated with DGAT1i + DGAT2i for 24h. Cell nuclei were counterstained with DAPI (blue). (F) Cell viability of spheroid A549 cells incubated without or with H 2 O 2 (250 μM) and/or indicated DGAT inhibitors (10 μM) for 24 h (G, H, and I) TAG, MDA, and 4-HNE levels in spheroid A549 cells incubated without treatment (CTR), treated with H 2 O 2 (250 μM), treated with DGATi (DGAT1 inhibitor at 10 μM + DGAT2 inhibitor at 10 μM), or in combination with H 2 O 2 and DGATi for 24 h. Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Increased TAG Synthesis in Lung CSCs via Upregulation of DGAT1/2 Expression. (A) Gene ontology (GO) analysis of RNA-sequencing data to identify spheroid-enriched genes between adherent and spheroid culture of A549 and H1993 cells. (B) Genes identified in TAG biosynthesis process term. (C) Western blot showing protein expression related to TAG biosynthesis process in adherent and spheroid culture. (D) Measurement of TAG levels in spheroid A549 cells treated with vehicle, DGAT1i (DGAT1 inhibitor, PF-04620110, 10 μM), DGAT2i (DGAT2 inhibitor, PF-06424439, 10 μM), or DGAT1i + DGAT2i for 24 h. (E) BODIPY 493/503 staining (green) for lipid droplets in spheroid A549 cells treated with DGAT1i + DGAT2i for 24h. Cell nuclei were counterstained with DAPI (blue). (F) Cell viability of spheroid A549 cells incubated without or with H 2 O 2 (250 μM) and/or indicated DGAT inhibitors (10 μM) for 24 h (G, H, and I) TAG, MDA, and 4-HNE levels in spheroid A549 cells incubated without treatment (CTR), treated with H 2 O 2 (250 μM), treated with DGATi (DGAT1 inhibitor at 10 μM + DGAT2 inhibitor at 10 μM), or in combination with H 2 O 2 and DGATi for 24 h. Data are presented as mean ± SD (one-way ANOVA followed by Tukey's post-hoc test). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Expressing, RNA Sequencing, Western Blot, Staining, Incubation

    Inhibition of Tumor Growth and Clinical Implications of DGAT1 and DGAT2 Suppression in Lung Cancer. (A) Cell viability was assessed after irradiation with 2 Gy, 4 Gy, or 6 Gy for 24 h in adherent and spheroid A549 cells. (B) Surviving fractions were calculated in adherent and spheroid A549 cells following irradiation with doses of 2 Gy, 4 Gy, or 6 Gy over a period of 7 days. (C) Cancer cells were subcutaneously injected. When the tumor size reached approximately 50 mm 3 , the mice were subjected to gamma irradiation (3 × 6 Gy) on days 0, 3, and 6, and tumor volumes were measured on the specified days. (D and E) Cell viability and surviving fractions in spheroid A549 cells with DGAT1 and/or DGAT2 inhibitors after irradiation with 6 Gy. (F) Spheroid A549 cells were subcutaneously injected. When the tumor size reached approximately 50 mm 3 , the mice underwent gamma irradiation (3 × 6 Gy) and were orally administered either a vehicle, a DGAT1 inhibitor (10 mg/kg body weight), or a DGAT2 inhibitor (10 mg/kg body weight) on day 0, day 3, and day 6. (G) Sphere formation in spheroid A549 cells with DGAT1 and/or DGAT2 knockdown. (H) The capability of tumor initiation was assessed through the subcutaneous injection of spheroid A549 cells with DGAT1 and/or DGAT2 knockdown. (I) Immunohistochemical staining of DGAT1 and DGAT2 in patients with lung cancer. Case 1 represents a patient with low expression of DGAT1 and DGAT2. Case 2 represents a patient with high expression of DGAT1 and DGAT2. (J) The survival curves of lung cancer patients with or without DGAT1 and DGAT2 expression (n = 59). Significance is calculated using the Kaplan-Meier method and comparisons are performed using the log-rank test. (K) Survival analysis of the 6-gene signature related to TAG synthesis in lung cancer. Data are presented as mean ± SD (student's two-tailed unpaired t -test is employed in A and B; two-way ANOVA followed with Tukey's multiple comparison test is employed in C; one-way ANOVA followed by Tukey's post-hoc test is employed in D, E, F, and G). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Inhibition of Tumor Growth and Clinical Implications of DGAT1 and DGAT2 Suppression in Lung Cancer. (A) Cell viability was assessed after irradiation with 2 Gy, 4 Gy, or 6 Gy for 24 h in adherent and spheroid A549 cells. (B) Surviving fractions were calculated in adherent and spheroid A549 cells following irradiation with doses of 2 Gy, 4 Gy, or 6 Gy over a period of 7 days. (C) Cancer cells were subcutaneously injected. When the tumor size reached approximately 50 mm 3 , the mice were subjected to gamma irradiation (3 × 6 Gy) on days 0, 3, and 6, and tumor volumes were measured on the specified days. (D and E) Cell viability and surviving fractions in spheroid A549 cells with DGAT1 and/or DGAT2 inhibitors after irradiation with 6 Gy. (F) Spheroid A549 cells were subcutaneously injected. When the tumor size reached approximately 50 mm 3 , the mice underwent gamma irradiation (3 × 6 Gy) and were orally administered either a vehicle, a DGAT1 inhibitor (10 mg/kg body weight), or a DGAT2 inhibitor (10 mg/kg body weight) on day 0, day 3, and day 6. (G) Sphere formation in spheroid A549 cells with DGAT1 and/or DGAT2 knockdown. (H) The capability of tumor initiation was assessed through the subcutaneous injection of spheroid A549 cells with DGAT1 and/or DGAT2 knockdown. (I) Immunohistochemical staining of DGAT1 and DGAT2 in patients with lung cancer. Case 1 represents a patient with low expression of DGAT1 and DGAT2. Case 2 represents a patient with high expression of DGAT1 and DGAT2. (J) The survival curves of lung cancer patients with or without DGAT1 and DGAT2 expression (n = 59). Significance is calculated using the Kaplan-Meier method and comparisons are performed using the log-rank test. (K) Survival analysis of the 6-gene signature related to TAG synthesis in lung cancer. Data are presented as mean ± SD (student's two-tailed unpaired t -test is employed in A and B; two-way ANOVA followed with Tukey's multiple comparison test is employed in C; one-way ANOVA followed by Tukey's post-hoc test is employed in D, E, F, and G). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: Inhibition, Irradiation, Injection, Knockdown, Immunohistochemical staining, Staining, Expressing, Two Tailed Test, Comparison

    Regulation of Lipid Metabolism by Cancer Stem Cells via the YAP1/TEAD Pathway. (A) Top pathways identified by KEGG analysis from RNA-sequencing data between adherent and spheroid culture of A549 and H1993 cells. (B) Representative immunofluorescence images showing the subcellular location of pYAP1 (Y357) and TEAD1 in adherent and spheroid A549 cells. Cell nuclei were counterstained with DAPI. (C) Western blot analysis of cytoplasmic (Cyt) and nuclear (Nuc) fractions revealing pYAP1 (Y357) and YAP1 protein expression in the adherent and spheroid culture of A549 cell cultures. (D) Co-immunoprecipitation of the nuclear fraction to detect the interaction between pYAP1 (Y357) and TEAD1. (E) Representative images of proximity ligation assay (PLA) illustrating protein-protein interactions between pYAP1 (Y357) and TEAD1. (F) ChIP-qPCR analysis using TEAD1 antibody to confirm protein-crosslinked genomic DNA fragments. (G) Western blot showing protein expression of ACSL1, ACSL4, DGAT1, DGAT2, LPIN2 and PNPLA3 in spheroid culture treated without or with 10 μM verteporfin (VP) for 24 h. (H and I) Assessment of TAG levels and cell viability in spheroid A549 cells treated without (CTR) or with 10 μM VP. (J) Western blot showing ACSL1, ACSL4, DGAT1, DGAT2, LPIN2 and PNPLA3 protein expression in spheroid A549 cells with YAP1 or TEAD1 knockdown. (K) Reduced TAG levels in spheroid A549 cells with YAP1 or TEAD1 knockdown. (L) Cell viability of spheroid A549 cells treated with or without YAP1 or TEAD1 knockdown, followed by treatment with H 2 O 2 (250 μM) for 24 h. Data are presented as mean ± SD (student's two-tailed unpaired t -test is employed in F and G; one-way ANOVA followed by Tukey's post-hoc test is employed in K and L). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: YAP/TEAD-activated TAG synthesis and peroxidation in lipid droplets confer ROS resistance in cancer stem cells

    doi: 10.1016/j.redox.2025.103968

    Figure Lengend Snippet: Regulation of Lipid Metabolism by Cancer Stem Cells via the YAP1/TEAD Pathway. (A) Top pathways identified by KEGG analysis from RNA-sequencing data between adherent and spheroid culture of A549 and H1993 cells. (B) Representative immunofluorescence images showing the subcellular location of pYAP1 (Y357) and TEAD1 in adherent and spheroid A549 cells. Cell nuclei were counterstained with DAPI. (C) Western blot analysis of cytoplasmic (Cyt) and nuclear (Nuc) fractions revealing pYAP1 (Y357) and YAP1 protein expression in the adherent and spheroid culture of A549 cell cultures. (D) Co-immunoprecipitation of the nuclear fraction to detect the interaction between pYAP1 (Y357) and TEAD1. (E) Representative images of proximity ligation assay (PLA) illustrating protein-protein interactions between pYAP1 (Y357) and TEAD1. (F) ChIP-qPCR analysis using TEAD1 antibody to confirm protein-crosslinked genomic DNA fragments. (G) Western blot showing protein expression of ACSL1, ACSL4, DGAT1, DGAT2, LPIN2 and PNPLA3 in spheroid culture treated without or with 10 μM verteporfin (VP) for 24 h. (H and I) Assessment of TAG levels and cell viability in spheroid A549 cells treated without (CTR) or with 10 μM VP. (J) Western blot showing ACSL1, ACSL4, DGAT1, DGAT2, LPIN2 and PNPLA3 protein expression in spheroid A549 cells with YAP1 or TEAD1 knockdown. (K) Reduced TAG levels in spheroid A549 cells with YAP1 or TEAD1 knockdown. (L) Cell viability of spheroid A549 cells treated with or without YAP1 or TEAD1 knockdown, followed by treatment with H 2 O 2 (250 μM) for 24 h. Data are presented as mean ± SD (student's two-tailed unpaired t -test is employed in F and G; one-way ANOVA followed by Tukey's post-hoc test is employed in K and L). ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.

    Article Snippet: Human lung cancer cell line A549 was obtained from the ATCC and grown in F–12K (Corning, Manassas, VA, USA).

    Techniques: RNA Sequencing, Immunofluorescence, Western Blot, Expressing, Immunoprecipitation, Proximity Ligation Assay, Protein-Protein interactions, ChIP-qPCR, Knockdown, Two Tailed Test